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FluorescenceCurcumin is an antioxidant and anti-inﬂammatory bioﬂavonoid that has been recently identiﬁed as an anti-
amyloid agent as well. To make it more available in its potent form as a potential amyloid disaggregation
agent, we employed high-density lipoproteins (HDL), which are lipid–protein complexes that transport
plasma cholesterol, to transport curcumin. The objective of this study was to employ reconstituted HDL
containing human apoE3 N-terminal (NT) domain, as a vehicle to transport curcumin. The NT domain serves
as a ligand to mediate binding and uptake of lipoprotein complexes via the low-density lipoprotein receptor
(LDLr) family of proteins located at the cell surface. Reconstituted HDL was prepared with phospholipids and
recombinant apoE3-NT domain in the absence or presence of curcumin. Non-denaturing polyacrylamide gel
electrophoresis indicated that the molecular mass and Stokes' diameter of HDL bearing curcumin were
~670 kDa and ~17 nm, respectively, while electron microscopy revealed the presence of discoidal particles.
Fluorescence emission spectra of HDL bearing (the intrinsically ﬂuorescent) curcumin indicated that the
wavelength of maximal ﬂuorescence emission (λmax) of curcumin was ~495 nm, which is highly blue-shifted
compared to λmax of curcumin in solvents of varying polarity (λmax ranging from 515–575 nm) or in aqueous
buffers. In addition, an enormous enhancement in ﬂuorescence emission intensity was noted in curcumin-
containing HDL compared to curcumin in aqueous buffers. Curcumin ﬂuorescence emission was quenched to
a signiﬁcant extent by lipid-based quenchers but not by aqueous quenchers. These observations indicate that
curcumin has partitioned efﬁciently into the hydrophobic milieu of the phospholipid bilayer of HDL.
Functional assays indicated that the LDLr-binding ability of curcumin-containing HDL with apoE3-NT is
similar to that of HDL without curcumin. Taken together, we report that apoE-containing HDL has a
tremendous potential as a ‘nanovehicle’ with a homing device to transport curcumin to target sites.Biochemistry, 1250 Bellﬂower
each, CA 90840, USA. Tel.: +1
ami).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Curcumin (diferuloylmethane) is a polyphenolic phytochemical
derived from the rhizome of Curcuma species, Zingiberaceae. It has
been under intense scrutiny over the past two decades for its potent
antioxidant, anti-inﬂammatory and cancer chemopreventive proper-
ties [1,2]. In addition, recent studies indicate a role for curcumin as a
potential anti-amyloid agent due to its ability to inhibit amyloid beta
peptide (Aβ) oligomerization and ﬁbril formation in vitro [3], suppress
Aβ accumulation and alleviate cognitive decline in vivo in Alzheimer's
disease (AD) patients [4], lower amyloid deposition [5] and disrupt
existing amyloid plaques in an AD transgenic mouse model [6].
Poorly soluble in water and typically soluble in solvents, the ability
of curcumin (Fig. 1) to inhibit Aβ aggregation and ﬁbril formationmaypossibly be related to its structural resemblance to Congo Red, a well-
established amyloidophilic dye [4]. However, unlike Congo Red,
curcumin is lipophilic and non-toxic. A majority of curcumin that is
administered by oral and intra-peritoneal routes is conﬁned to the
gastrointestinal tract and undergoes metabolism to more polar and
less potent derivatives such as the glucuronide and sulfate metabo-
lites [7–12]. The poor systemic and plasma bioavailability of the active
form of curcumin may pose a limitation on its usage as a potent
therapeutic/nutraceutical agent to treat diseases outside the gastro-
intestinal tract. Its increased availability at the neurovascular junction
of the cerebral microvasculature forming the blood brain barrier will
be particularly desirable to treat neurological disorders such as AD
and cerebrovascular amyloidosis.
In this study, we propose to load curcumin on to high-density
lipoproteins (HDL), which are protein/lipid complexes that normally
play a role in cholesterol transport in the plasma. Typically, plasma
HDL may be spherical (~20 nm diameter) containing a core of neutral
lipids like cholesteryl ester surrounded by amphipathic lipids such as
phospholipids and cholesterol, and proteins such as apolipoproteins,
Fig. 1. Structure of curcumin. Curcumin (IUPAC name: 1,7-bis(4-hydroxy-3-methox-
yphenyl)-1,6-heptadiene-3,5-dione) is the major curcuminoid of the spice turmeric. It
has the capability of undergoing keto-enol tautomerization. The enol form (shown
here) is more stable in solution under physiological conditions.
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composed of a bilayer of phospholipids (and cholesterol) surrounded
by apolipoproteins [13]. Discoidal HDL can be reconstituted using
apolipoprotein E3 (apoE3) or apolipoprotein AI (apoAI), another
member of the apolipoprotein family, and are well-characterized in
terms of their biophysical and biochemical characteristics [14]. They
recapitulate the functional and structural features of native HDL
isolated from the plasma. Importantly, the hydrophobic interior of the
particle surrounded by the amphipathic helices of apolipoproteins
offers an ideal environment to ‘package’ and transport curcumin in a
predominantly aqueous environment such as the plasma.
Previous studies from our lab have derived structure–function
relationships regarding apoE3 (reviewed in [14] and [15]), an anti-
atherogenic protein that plays a critical role in regulating plasma and
brain cholesterol homeostasis [16]. Considered an important protein
in cardiovascular and Alzheimer's disease, apoE is an exchangeable
apolipoprotein composed of an N-terminal (NT) domain (residues 1–
191) and a C-terminal domain (201–299) linked by a protease-
sensitive loop. The NT domain is a 4-helix bundle [14,17], which bears
high-afﬁnity binding sites for the cell-surface localized low density
lipoprotein (LDL) receptor (LDLr) family of proteins [18]. Only lipid-
associated apoE appears to bind to the LDLr; the binding leads to
internalization and cellular uptake of the entire lipoprotein particle by
receptor-mediated endocytosis. For LDLr binding to occur, the lipid-
associated apoE may be in the form of very low density lipoproteins
(VLDL) [19], nativeHDL [20] or reconstitutedHDL containing synthetic
phospholipids in the absence or presence of cholesterol [21]. In the
present study, apoE-containing reconstituted HDL was deemed the
ﬂavonoid transporter of choice due to the ease of preparation of these
particles, their well-characterized nature [15] and to the ability of
these particles to interact with the LDLr. This will allow targeting of
curcumin-loaded HDL to cells expressing LDLr. Our studies indicate
that curcumin partitions efﬁciently into HDL as evidenced by
ﬂuorescence analysis, and that curcumin-bearing HDL prepared with
apoE3-NT retains the structural integrity and a robust LDLr-binding
activity comparable to those of HDL without curcumin.2. Materials and methods
2.1. Chemicals
Potassium iodide (KI) and sodium thiosulfate were obtained from
Fisher Scientiﬁc (Fair Lawn, NJ). Curcumin (98+% pure) as a mixture
of curcumin, demethoxycurcumin and bisdemethoxycurcumin was
obtained fromACROSORGANICS (Fair Lawn,NJ). 5 DOXYL-stearic acid,
free radical (5-DSA) and 16 DOXYL-stearic acid, free radical (16-DSA)
were purchased from Sigma-Aldrich (St. Louis, MO). Sephadex G-75
was from G.E. Healthcare (Uppsala, Sweden). Dimyristoylphosphati-
dylcholine (DMPC) was obtained from Avanti Polar Lipids (Alabaster,
AL). The phospholipid assay kit was from Wako Chemicals USA, Inc.
(Richmond, VA), the DC and the BCA kits for protein assay were from
BioRad Laboratories (Hercules, CA) and Thermoscientiﬁc (Rockford,
IL), respectively. All solvents used were of analytical grade.2.2. Expression, isolation and puriﬁcation of apoE3-NT
Recombinant human apoE3 residues 1–191 bearing a hexa-His tag
at the N-terminal end was over-expressed in E. coli, isolated and
puriﬁed using a Ni-afﬁnity matrix (Hi-Trap chelating column, G.E.
Healthcare, Uppsala, Sweden) as described earlier [22,23]. Protein
purity was veriﬁed by SDS-PAGE analysis using a 4–20% acrylamide
gradient.
2.2.1. Reconstitution and characterization of HDL with curcumin
Reconstituted HDL containing dimyristoylphosphatidylcholine
(DMPC) and apoE3-NT (5:2 w/w starting ratio) were prepared by the
sonication method as described previously [24] and will be referred to
as HDL throughout this study unless otherwise speciﬁed. HDL contain-
ing curcumin were prepared in a similar manner except that curcumin
was includedwhilemaking theDMPC thinﬁlm (Lipid:protein:curcumin
ratio of 5:2:5 w/w). Lipid-free protein and curcumin not bound to HDL
were separated from protein/lipid/curcumin ternary HDL complexes by
gel ﬁltration chromatography using Sephadex G-75 or by density
gradient ultracentrifugation using KBr gradient. Fractions containing
both protein and phospholipid were pooled based on absorbance at
280 nmand phospholipid assay, respectively. The presence of curcumin
wasdeterminedbymonitoring the absorbanceof the individual fractions
at 420 nm (molar extinction coefﬁcient, 49,000 M−1 cm−1). Fractions
containing co-localized protein, lipid and curcumin were pooled,
concentrated and electrophoresced by agarose gel electrophoresis [25]
using the TITAN GEL lipoprotein electrophoresis kit as described by the
manufacturer (HelenaLaboratories, Beaumont, TX). After electrophoresis
the lipoproteins were transferred to a PVDFmembrane by diffusion [26],
the membranes probed with anti-apoE antibody mAb1D7 (Lipoproteins
& Atherosclerosis Research Group, University of Ottawa Heart Institute,
Ottawa, Ontario, Canada), and visualized by chemiluminescence using
goat anti-mouse IgG-HRP (Millipore, Billerica, MA). HDL prepared in the
absence or presence of curcumin was examined under a transmission
electron microscope (Philips Electron Optics, Eindhoven, Netherlands)
after negative staining with 1% phosphotungstate as described earlier
[27].
2.3. Fluorescence spectroscopy
Steady state ﬂuorescence analyses were performed on a Perkin-
Elmer LS55B ﬂuorometer at 24 °C. A stock solution of 5 mM curcumin
was prepared in DMSO. Fluorescence emission spectra of curcumin
were recorded in solvents of varying polarity and dielectric constant
or in 10 mM sodium phosphate pH 7.4 containing 150 mM NaCl
(phosphate-buffered saline or PBS) or in PBS containing 0.1% TX-100.
The samples were excited at 420 nm and the emission spectra were
recorded between 450 and 650 nm. The excitation and emission slit-
widths were set at 5 nm and the scan speed at 50 nm/min; typically 3
scans were averaged.
2.4. Quenching studies
To verify the location of curcumin in the HDL, the ﬂuorescence
emission of curcumin was quenched with KI and spin-labeled fatty
acids (5-DSA and 16-DSA) as described earlier [28]. Brieﬂy, ﬂuores-
cence quenching studies were performed by addition of small
increments of stock solutions of KI in buffer or 5-DSA or 16-DSA
(stock solutions in DMSO) directly to 400 μl of HDL with curcumin in
PBS (50 μg protein). In experiments where DMSO was used, the ﬁnal
concentration of the solvent was always ≤5% v/v. The KI stock
solutions contained 1 mM sodium thiosulfate to prevent formation of
free iodine. The ﬂuorescence emission intensities were recorded at
495 nm in the absence and presence of varying amounts of quenchers.
The apparent Stern–Volmer quenching constants (KSV) were calculated
employing the Stern–Volmer equation, F0/F=1+KSV [Q],where F0 and F
Fig. 2. Isolation of HDL containing curcumin by gel ﬁltration chromatography. HDL with
(panel A) or without (panel B) curcumin was applied to a Sephadex G-75 gel ﬁltration
column at a ﬂow rate of 1 ml/min in PBS. The fractions were analyzed for the presence
of protein (dotted line) and curcumin (bold line) by monitoring the absorbance at
280 and 420 nm, respectively. Inset. SDS-PAGE analysis of individual fractions was
performed to visualize the presence of apoE3-NT. Lane 1 in both gels represents the low
molecular weight standard with the indicated molecular masses. In panel A, lanes 2 to
10 represent elution volumes in 1.2 ml increments between 20.4 and 30 ml, while in
panel B lanes 2 to 10 represent elution volumes in 1.5 ml increments between 21 and
33 ml.
Fig. 3. Density gradient ultracentrifugation of HDL with curcumin. HDL containing
curcumin was separated from lipid-free protein and curcumin not bound to HDL by
density gradient ultracentrifugation as described previously [24]. The image shows co-
localization of curcumin with lipoprotein complexes (arrow) that migrate to densities
corresponding to that of HDL in a KBr gradient.
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quencher concentrations, respectively, and [Q] is the quencher
concentration [29–31].
2.5. Dose-dependent loading of curcumin into HDL
To determine the amount of curcumin that can be loaded on to
a pre-existing HDL particle, 10 μg HDL protein was treated with
increasing concentrations of curcumin in DMSO, and incubated at
37 °C for 6 h. Fluorescence emission spectra of the samples were
recorded and the ﬂuorescence emission intensity at 495 nm plotted
versus curcumin concentration. The size of the particles in the absence
or presence of varying amounts of curcumin was determined by non-
denaturing polyacrylamide gel electrophoresis (PAGE) on a 4–20%
acrylamide gradient. Following gel electrophoresis, the lipoproteins
were visualized using Amido Black stain.
2.6. LDLr binding assay
To assess whether curcumin loading affected the LDLr binding
activity of HDL with apoE3-NT, we performed an a co–immunopre-
cipitation (co–IP) analysis, as described earlier [32,33]. A construct
bearing the LDLr ligand binding domains 3–6 with a c-Myc epitope
was employed. This construct represents the essential ligand binding
elements of the extra cellular soluble portion of the mature LDLr and
will be represented as sLDLr unless otherwise speciﬁed. HDL (5 μg
apoE3-NT protein) prepared with or without curcumin was incubated
with 5 μg of sLDLr in the presence of Ca2+ for 16 h at 4 °C, followed by
IP using anti-c-Myc-Agarose (Sigma-Aldrich, St. Louis, MO). sLDLr-
bound apoE was detected by Western blot using HRP-conjugated
polyclonal apoE antibody. In control reactions, the HDLwas omitted in
the incubation mixture.
3. Results and discussion
A characteristic feature of apolipoproteins is their ability to trans-
formphospholipid vesicles to discoidal bilayer protein–lipid complexes.
The protein–lipid complexes resemble nascent pre-β HDL [34,35] gen-
erated in vivo; they are composed of a bilayer of phospholipids that are
encircled by a series of amphipathic α-helices of the apolipoproteins,
which prevent exposure of the hydrophobic fatty acyl chains of the
phospholipids to the aqueous environment. In this arrangement, the
helical axes of the protein are oriented perpendicular to the fatty acyl
chains of the phospholipids [36,37]; the hydrophobic face of the helices
is oriented towards the fatty acyl chains and the polar side chains face
the aqueous environment. In the present study, we take advantage of
the presence of the hydrophobic milieu of the lipid interior of the HDL
particle as a discrete environment to package the highly hydrophobic
curcuminmolecules. The presence of the receptor-binding sites on helix
4 of apoE3-NT [17] is a desirable feature since it facilitates ‘homing’ and
lipoprotein receptor binding.
HDL with (Fig. 2A) or without (Fig. 2B) curcumin was applied to
a gel ﬁltration column at a ﬂow rate of 1 ml/min and the fractions
were monitored at 280 and 420 nm for the presence of protein and
curcumin, respectively. The presence of apoE3-NT in individual
fractions was also visualized by SDS-PAGE (insets in Fig. 2A and B).
It must be pointed out that curcumin displays signiﬁcant absorbance
at 280 nm, which likely accounts for the high absorbance noted for
fractions containing HDL with curcumin (Fig. 2A). The phospholipid
content in each fraction was determined to verify the presence of
lipids (data not shown). In separate experiments, HDL prepared with
or without curcumin was also isolated by density gradient ultracen-
trifugation. Fig. 3 shows the image of the tube containing HDL and
curcumin prior to fractionation. Each fraction was analyzed for the
presence of protein, lipid and curcumin and the protein visualized by
SDS-PAGE analysis. As indicated by the arrow in the ﬁgure, curcuminco-localizes with fractions containing protein and lipid, at densities
corresponding to those of HDL in a KBr gradient (1.063–1.21 g/ml)
[25]. In both isolation protocols, fractions containing co-localized
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without curcuminwas isolated in an identicalmanner. All data reported
in this study were obtained with HDL isolated by the gel ﬁltration
method; similar results were obtained (data not shown)whenHDLwas
isolated by density gradient ultracentrifugation approach.
Agarose gel electrophoresis and electron microscopic analysis of
HDL in the presence and absence of curcumin were carried out
(Fig. 4). The agarose gel was stained for lipid (data not shown as
the lipid stains used have a low afﬁnity for phospholipids) and
independently evaluated for protein by Western blot analysis
(Fig. 4A). Immunoblot of the agarose gel revealed that the electro-
phoretic mobility of apoE3-NT containing HDL particles with
curcumin is similar to that of apoE3-NT HDL without curcumin and
that they migrate with similar mobility to zones intermediate be-
tween the alpha and beta positions as described by Sparks & Phillips
for apoAI [25]. Electron microscopy of the lipoprotein complexes in
the presence of curcumin (Fig. 4B), revealed the formation of HDL-
like particles with an average diameter of 25.1±0.2nm (n=87) seen
as both stacked and en face discoidal structures. The geometry and
size were comparable to those of HDL without curcumin (Fig. 4C),
with average diameters of 23.7±0.1 nm (n=176). Panel B has fewer
discoidal particles as the sample was dilute. Both panels display
sample heterogeneity, consistent with the observations from lipogel
analysis. These studies conﬁrm that the presence of curcumin does
not signiﬁcantly alter the structural integrity, geometry or size of the
HDL particle [24]. Particle composition analysis reveals that the lipid
to protein ratio of HDL with curcumin is about 70:1 (M/M) and
curcumin:protein ratio of about 8:1.
We took advantage of the intrinsic ﬂuorescence of curcumin to
determine if curcumin is present within the HDL particle or if it simply
co-migrated with the HDL loosely bound to the external surface of
the particle. In the former case, the environment of the curcumin
molecules in the phospholipid bilayer within the head group region
can be expected to be hydrophobic; however, in the latter case it can
be expected to be polar, which is reﬂective of the nature of the aqueous
environment surrounding the HDL particle. To address this issue,
in initial experiments, ﬂuorescence emission analysis of curcumin
(~0.1 μg/ml) was carried out in solvents of varying polarity, such
as methanol (a), ethanol (b), tetrahydrofuran (c) and ethyl acetate
(d) (dielectric constants of 33.0, 24.3, 7.5 and 6.0, respectively) to
obtain a correlation between the microenvironment polarity and
ﬂuorescence emission characteristics of curcumin (Fig. 5, panel A).Fig. 4. Agarose gel electrophoresis and electron micrographs of HDL without and with
curcumin. Lipoprotein gel electrophoresis of HDL (1 μg apoE3-NT) (panel A) was
performed in an agarose gel. The electrophoresis was carried out at 80 V for 45 min
followed by diffusion transfer of proteins to PVDF membrane andWestern blot analysis
using anti-apoE antibody (mAb1D7). Lane 1: HDL with curcumin; lane 2: HDL without
curcumin. Electron microscopic analysis of HDL with (panel B) or without curcumin
(panel C) was carried out following negative staining of the particles with 1%
phosphotungstate. The bar represents 50 nm.Curcumin was soluble in these solvents (more readily soluble in
tetrahydrofuran and ethyl acetate). The wavelength of maximal
ﬂuorescence emission intensity (λmax) was ~570 nm in methanol,
~559 nm in ethanol, ~518 nm in tetrahydrofuran and ~514 nm in
ethyl acetate. It is noted that as the solvent polarity decreases, there is a
corresponding decrease in theλmax. This blue shift is accompanied by a
general increase in the ﬂuorescence emission intensity, a behavior
predicted to occur with ﬂuorophores present in a less polar solvent
[39]. In contrast, curcumin displays little or no ﬂuorescence emission
in aqueous buffers such as PBS (in which it is poorly soluble) (Fig. 5,
panel B, spectrum a). In the presence of detergent micelles such as
0.1% TX-100 (spectrum b), curcumin displays intense ﬂuorescence
emission with a λmax at 493 nm. The increased intensity and blue-
shifted spectrum are indicative of interaction of curcumin with the
detergent micelles and relocation to the hydrophobic interior of the
micellar structure. Interestingly, curcumin that has co-migrated with
the HDL fraction displays a λmax of ~495 nm, with a shoulder~470 nm
(spectrum c). From this observation, we infer that curcumin has
relocated into the hydrophobic environment in the interior of the
phospholipid bilayer of the HDL. The shoulder may represent the
presence of a second population of curcumin in a discrete microen-
vironment within a single particle in addition to those in the hydro-
phobicmilieu; one such site is at the protein–lipid interface of the HDL
where the non-polar surface of the amphipathic helices around the
particle perimeter face the fatty acyl chains of the phospholipid
bilayer. Alternatively, the shoulder may be due to the presence of sub-
populations of HDL (as noted in Fig. 4 by agarose gel electrophoresis,
in Fig. 5 by non-denaturing PAGE) into which curcumin was
distributed. Lastly, the possibility that the spectrum represents the
two tautomeric forms of curcumin cannot be excluded at this point, as
it is believed that curcumin can undergo keto-enol tautomerization
under physiological conditions [2].
To determine if HDL loading of curcumin is saturable, increasing
amounts of curcumin (5 mM stock dissolved in DMSO) was incubated
with HDL (10 μg protein) at 37 °C for 6 h. Fluorescence emission
spectra of the incubation mixtures revealed a gradual increase in
ﬂuorescence emission intensity with increasing curcumin concentra-
tion. Fig. 5, panel C shows a plot of ﬂuorescence emission intensity at
495 nm versus concentration of added curcumin. The curve is reﬂec-
tive of a steady increase in localization of curcumin in a lipophilic
environment followed by a plateau around 50 μM curcumin, indica-
tive of saturable binding. Non-denaturing PAGE of HDL that was
incubated with 0, 50 or 500 μg curcumin (added directly to 50 μg
HDL protein) revealed the presence of protein/lipid complexes with
an apparent molecular mass of ~670 kDa (Fig. 5, panel D). This
corresponds to a particle diameter of ~17 nm based on the Stokes'
diameter of the standards (note that the diameter obtained from the
electron micrographs was ~25 nm). The differences noted in the par-
ticle diameters obtained from two different methods are attributed to
the limitations inherent with eachmethod. Typically, the diameters of
lipoprotein particles obtained from electron microscopy measure-
ments are signiﬁcantly higher than those from other methods such as
non–denaturing PAGE [40,41]. While neither approaches yield
accurate information regarding particle diameter, we believe that
the diameter of the reconstituted HDL bearing curcumin is in the
range generally observed for apoE-containing particles prepared in
similar ways [24,42]. Previously, we suggested that there may be 4–6
apoE3-NT/discoidal particle based on particle composition and size
[38]. Employing similar calculations, we estimate that under the
current preparation conditions wherein curcumin is added during the
reconstitution procedure, each HDL particle has 30–50 curcumin
molecules. However, from the dose-dependent ﬂuorescence analysis,
it appears that the HDL particle may be able to accommodate at least
three times more curcumin. Further studies are needed to verify this
possibility and to understand the loading capacity and stability of a
loaded HDL particle.
Fig. 5. Fluorescence emission spectra of curcumin. Panel A shows ﬂuorescence emission spectra of curcumin in solvents of varying polarity such as methanol (a), ethanol (b),
tetrahydrofuran (c) and ethyl acetate (d) with dielectric constants of 33.0, 24.3, 7.5 and 6.0, respectively. The spectra were recorded between 450 and 650 nm following excitation at
420 nm. Panel B shows ﬂuorescence emission spectra of curcumin in PBS (a), 0.1% TX-100 (b) or reconstituted HDL (15 μg protein) (c). Panel C shows the dose-dependent
accumulation of curcumin in HDL. Curcumin (5 mM stock dissolved in DMSO) was added in incremental amounts to HDL (10 μg apoE protein) and incubated at 37 °C for 6 h. The
ﬂuorescence emission intensities at 495 nm were plotted versus the ﬁnal curcumin concentration in the incubation mixture. A representative plot from 3 different experiments is
shown. Panel D. Non-denaturing PAGE of HDL in the presence of varying amounts of curcumin. HDL was incubated with 0, 50 and 500 μg curcumin (added to 50 μg HDL protein) as
described above, electrophoresced on 4–20% acrylamide gradients (lanes 2, 4 and 5, respectively) and stained with Amido Black. Lanes 1 and 3 show high molecular weight
standards, thyroglobulin (669 kDa) and ferritin (440 kDa) bearing Stokes' diameter of 17 and 12.2 nm, respectively.
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ﬂuorescence emission of curcumin was quenched using quenchers
that are known to be water-soluble (KI) or lipid-soluble (5-DSA and
16-DSA). The rationale behind this analysis is that KI represents a class
of aqueous, dynamic quenchers that involve collision between a
ﬂuorophore and a heavy atom (such as iodide ion in this case); thus, if
curcumin is located on the periphery of the HDL facing the aqueous
environment, its ﬂuorescence will be quenched readily by KI. On the
other hand, fatty acids are lipophilic molecules that partition rapidly
into the phospholipid bilayer; the DOXYL spin labels present on the
fatty acid are excellent quenchers of ﬂuorescence emission. If
curcumin is present in the hydrophobic milieu of the phospholipid
bilayer of the HDL, its ﬂuorescence will be quenched efﬁciently by the
DOXYL group on the fatty acid. Fatty acids are expected to insert into
the lipid bilayer with the hydrophobic tail facing inward and the
carboxylic acid facing the aqueous environment. Further by compar-
ing the quenching constants using 5-DSA and 16-DSA, we can
estimate the depth of location of curcumin in the preparations since
the DOXYL group (on C16 position) in 16-DSA will be located deeper
than that in 5-DSA. Fig. 6A and C show plots of F/F0 versus quencher
concentration for quenching of curcumin ﬂuorescence by increasing
concentrations of KI and DOXYL-stearic acids, respectively. Both
DOXYL-stearic acids were far more powerful quenching agents com-
pared to KI, displaying apparent Stern–Volmer quenching constantsof 7.37±1.71×10−3 M−1 for 16-DSA and 2.45±0.43×10−3 M−1 for
5-DSA (Fig. 6D) versus 0.23±0.04 M−1 for KI (Fig. 6B). An interesting
observation that emerged upon comparison of the quenching curves
of the two DOXYL-stearic acids is that the KSV for 16-DSA is about 3-
fold higher than that for 5-DSA. From these observations, we propose
that curcumin is located deep within the lipid bilayer in the HDL, an
inference that derives further supporting evidence from the highly
blue-shifted ﬂuorescence emission spectrum of curcumin (Fig. 5B,
spectrum c).
Lastly, an LDLr binding assay was performed by IP analysis as
described previously [32,33] to determine if curcumin-loaded HDL
retains its functional ability. HDL (5 μg apoE3-NT protein) prepared
with or without curcumin was incubated with sLDLr in the presence
of Ca2+ for 16 h at 4 °C. The sLDLr/HDL complex was captured by
incubation with anti-c-Myc-Agarose, followed by Western blot
analysis to detect apoE, Fig. 7. The presence of a band corresponding
to the 22-kDa apoE3-NT indicates an ability of HDL to interact with
sLDLr. HDL with curcumin (lane 2) displays a robust binding with
sLDLr, similar to that displayed by HDL without curcumin (lane 1). In
control incubations, apoE-bearing HDL was omitted; these samples
did not show sLDLr binding (lane 3). Lanes 4 and 5 are Western blot
controls containing reconstituted HDL with apoE (1 μg protein) in the
absence and presence of curcumin, respectively. The binding inter-
action between the LDLr and apoE3-NT involves participation of
Fig. 6. Quenching analysis of HDL with curcumin. HDL with curcumin (10 μg protein) was treated with increasing concentrations of KI in PBS (panels A and B) or DOXYL-stearic
acid in DMSO (panels C and D), and the ﬂuorescence emission intensity recorded at each concentration at 495 nm (excitation at 420 nm). KI, open triangles; 5-DSA, open circles, and
16-DSA, closed circles. The data are plotted as F/F0 versus quencher concentration (panels A and C), or as the Stern–Volmer plot of F0/F versus quencher concentration (panels B
and D). The Stern–Volmer quenching constants were obtained from the slopes of the line ﬁtted to the equation as described under Materials and methods. Data are represented as
mean±SD from 3 or 4 independent experiments.
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molecules on the HDL involved in co-operative binding. Our results
suggest that the presence of curcumin does not alter the ability of
HDL-bound apoE3 to interact with the LDLr. This feature can be
exploited in future studies to facilitate cellular uptake and internal-
ization of the curcumin-loaded HDL with apoE by receptor-mediated
endocytosis. Any cell type having the LDLr (or the family of receptors
for many of which apoE is a ligand) may beneﬁt from this mode of
delivery. It is noteworthy that the brain microvasculature endothelial
cells have signiﬁcantly higher expression of LDLr on the side facing
the vasculature [43] compared to the peripheral arterial endothelial
cells. This is because the latter lacks a constitutively functional LDLr
due to contact inhibition (being in constant contact with the physio-
logical concentration of LDL, there is a down-regulation of the LDLr
expression [43]). Thus, HDL bearing apoE may prove to be advan-
tageous to make curcumin more bioavailable at the neurovascular
junction lining the blood brain barrier.
In previous studies from other labs, similar protein–lipid complexes
formed as a result of self-assembly under appropriate conditions,
have been called nanodiscs since they are discoidal in shape bearing
diameters that are in the nanometer scale (~10 nm or lower). They
are soluble in aqueous environments and have been used to studyFig. 7. Effect of curcumin on sLDLr binding of HDL. HDL without or with curcumin (5 μg
protein) were incubated with 5 μg of sLDLr in 25 mM Tris–HCl, pH 7.4, 140 mM NaCl,
27 mMKCl, 2 mM CaCl2 for 16 h at 4 °C, followed by IP with anti-c-Myc-Agarose. sLDLr-
bound apoE was detected by Western blot using HRP-conjugated polyclonal apoE
antibody. The lane assignments are as follows: lane 1, HDL with no curcumin; lane 2,
HDL with curcumin; lane 3, no HDL. Lanes 4 and 5 represent Western blot controls
containing HDL (1 μg) without and with curcumin, respectively.membrane proteins [44–46] or to ‘package’ select small molecules of
pharmaceutical interest [47] with truncated apoAI as the membrane
scaffold protein that surrounds a bilayer containing dipalmitoylpho-
sphatidylcholine or palmitoyloleoylphosphatidylcholine. In our study,
we employed discoidal particles containing apoE, which, unlike apoAI,
has the ability to bind to the LDLr, for transport of curcumin in plasma
and targeted delivery to cell surfaces expressing the receptor family of
proteins. These HDL-like complexes bearing apoE are well-character-
ized [24,37,38,48], soluble, stable, and provide a discrete hydrophobic
environment to transport curcumin, protecting it from rapid metabo-
lism to less potent forms. Researchers have been able tomanipulate the
size of the nanodiscs [45] by varying the length of apoAI; the lipid:
protein molar ratio varied (ranging from 75:1 to 200:1) depending on
the nature of the lipid and the apoAI construct. Under the conditions
described in our case, we obtained larger discoidal particles with a ratio
of 70:1. The difference may be attributed to the use of apoE, higher
copy numbers of apoE/particle, and/or the presence of about 30–50
molecules of curcumin per particle in our preparations. More studies
are needed to determine if the loading capacity is related to the lipid
composition of the HDL.
ApoE-containing HDL particles are of direct relevance for curcumin
transport since apoE appears to be the primary apolipoprotein in the
CNS where it is located on HDL-sized particles [20,49,50]; no large
lipoprotein particles have been identiﬁed in the CNS. There appears to
be no major exchange of apoE and cholesterol between the vascular
system and CNS [51,52]. ApoE is one of the best known genetic risk
factors for AD with individuals homozygous for the APOE ε4 allele
having a 50–90% chance of developing AD by 85 years of age, while
heterozygous subjects have a chance of 45%. The amino acid at
position 112 differs in the two major isoforms, apoE3 and apoE4: it is
Cys in apoE3 and Arg in apoE4. The molecular basis for the difference
in their physiological and pathological behavior in AD is not fully
understood, and may involve a combination of factors [15].
Other groups have shown binding and/or stabilization of curcumin
following a direct binding interaction with serum albumin and ﬁbrin-
ogen [53–55]. Although these proteins represent a bulk of the
plasma proteins, HDL with apoE can serve as a versatile ‘nano-
vehicle’ to transport curcumin by providing a sheltered hydrophobic
358 P. Khumsupan et al. / Biochimica et Biophysica Acta 1808 (2011) 352–359microenvironment to decrease its degradation and therefore increase
its bioavailability, and to target curcumin due to the ability of apoE to
serve as a ligand for the LDLr. Additionally, it may serve as a potent
lipid-based antioxidant to protect LDL from oxidation, an aspect
investigated by some researchers studying partitioning of similar
ferulic acid derivatives into plasma lipoprotein fractions [56]. The
curcumin used in our study contains small amounts (2%) of
demethoxycurcumin and bisdemethoxycurcumin, both reported to
possess anti-inﬂammatory and antioxidant properties. However, their
potencies relative to curcumin appear to be widely variable depend-
ing on the system and the experimental conditions used, with reports
of similar potencies [57], lower potency [58,59], or higher potency for
the derivatives compared to that of curcumin [60].
3.1. Concluding remarks
In conclusion, use of reconstitutedHDLbearing the apoE3 receptor-
binding domain shows promise of increasing the bioavailability of
curcumin, and potentially other lipophilic agents, to possibly treat
inﬂammation, oxidative stress and complexneurological diseases such
as AD and cerebrovascular amyloidosis.
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